Proactive Investors
16 Jun 2026, 06:39 UTC · 2h ago
IP Group's Istesso starts phase II trial of leramistat in sarcopenia
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
16 Jun 2026, 06:39 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Istesso has commenced dosing patients in a phase II clinical trial for its lead drug candidate, leramistat, targeting sarcopenia caused by rheumatoid arthritis. — Advancing to Phase II is a critical value-inflection point for biotech assets, significantly reducing clinical risk and increasing the probability of commercialization.
+0.60IP Group PLC holds a 56.5% undiluted stake in Istesso. — The majority stake ensures that a substantial portion of any valuation uplift from the Phase II trial flows directly to IP Group shareholders.
+0.40Bango PLC has integrated LinkedIn Premium into its Digital Vending Machine platform for telcos, banks, and retailers. — Expanding the partnership ecosystem increases Bango's product appeal to B2B clients and opens new recurring revenue streams.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company's portfolio firm, Istesso, has progressed to a phase II clinical trial for its lead drug candidate.
The company expanded its Digital Vending Machine platform by adding LinkedIn, meeting growing demand for flexible subscription models.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
3h ago
